« Return to News | Awards & Advancement

A.P. Pharma raises $4.5 million, names new CEO

Tuesday, April 26, 2011 11:58 AM

California-based A.P. Pharma has raised $4.5 million in convertible notes and named a new CEO, according to Silicon Valley/San Jose Business Journal.  The specialty pharmaceutical company's lead drug candidate is designed to prevent acute-onset and delayed-onset chemotherapy-induced nausea and vomiting.

The private placement is through agreements with investors, including Tang Capital Partners LP.  At the closing, an amount of $1.5 million will be funded to the company and used directly to help resubmit the company's New Drug Application to the FDA. The $3 million that remains will be funded to the company at the investors’ discretion.

The company has also named John B. Whelan as president, chief executive officer and a director. Whelan has worked for A.P. Pharma since February 2009, most recently serving as acting chief executive officer and chief financial officer.

Share:          
CLINICAL TRIAL RESOURCES

Search:

NEWS ONLINE ARCHIVE

Browse by:

CWWeekly

September 30

Novartis-Walgreens pilot study blurring the line between retail pharmacy, investigative site

CISCRP to launch traveling science museum exhibit to demystify clinical trial participation

Already a subscriber?
Log in to your digital subscription.

Subscribe to CWWeekly.

The CenterWatch Monthly

October

New growth and decline in Asia clinical trials
South Korea, Japan, China see big growth in 1572s, while India posts huge drop

Harnessing Big Data to transform clinical trials
From protocol to patient recruiting, data analytics can yield valuable insights

Already a subscriber?
Log in to your digital subscription.

Purchase the October issue.

Subscribe to
The CenterWatch Monthly.

The CenterWatch Monthly

September

Sponsors look to collaborate on comparator drugs
Co-therapies, comparators are in 60% of studies, cost $25m per company a year

Early adopters implement risk-based monitoring pilot programs
Experiments aim to offer long-term solutions, despite short-term uncertainties

Already a subscriber?
Log in to your digital subscription.

Purchase the September issue.

Subscribe to
The CenterWatch Monthly.

JobWatch centerwatch.com/jobwatch

Featured Jobs

More Jobs

 

Copyright © 1995-2013 CenterWatch.